Petzinna Simon M, Küppers Jim, Schemmer Benedikt, Kernder Anna L, Bauer Claus-Jürgen, von der Emde Leon, Salam Babak, Distler Jörg H W, Winklbauer Anja, Essler Markus, Schäfer Valentin S
Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Front Immunol. 2024 Dec 16;15:1501790. doi: 10.3389/fimmu.2024.1501790. eCollection 2024.
This study aimed to evaluate the diagnostic utility of [Ga]Ga-DOTA-Siglec-9 positron emission tomography-computed tomography (PET/CT) in assessing disease activity in a patient experiencing a relapse of giant cell arteritis (GCA).
A 90-year-old male patient with GCA, diagnosed in 2018, was enrolled. Demographic data, disease history, and laboratory parameters, including soluble VAP-1 (sVAP-1) levels, were recorded. The patient underwent a [Ga]Ga-DOTA-Siglec-9 PET/CT scan. Additional imaging assessments included vascular ultrasound of the superficial temporal arteries, their branches, and the facial, axillary, subclavian, carotid, and vertebral arteries, along with magnetic resonance imaging (MRI) of the aorta.The patient's sVAP-1 level was 284 ng/ml compared to 123 ng/ml in the control group (SD ± 55). The [Ga]Ga-DOTA-Siglec-9 PET/CT scan revealed increased tracer uptake (SUVmax) in the subclavian artery (2.5), aortic arch (2.9), and heart (2.9). Notably, the increased uptake in the descending aorta (3.5) abruptly diminished to 2.2 when passing the diaphragm, with no changes in vessel caliber observed in CT. The injection of [Ga]Ga-DOTA-Siglec-9 was well tolerated. Aortic MRI revealed no signs of inflammatory involvement.
This study introduces the first application of [Ga]Ga-DOTA-Siglec-9 PET/CT in a patient with GCA experiencing a relapse, revealing enhanced tracer uptake in the subclavian artery and aortic arch with a localized and abrupt reduction, absent in conventional imaging. These findings suggest that [Ga]Ga-DOTA-Siglec-9 PET/CT has significant potential for precise, inflammation-specific detection of affected vascular tissue in GCA during relapse.
本研究旨在评估[镓]镓 - DOTA - Siglec - 9正电子发射断层扫描 - 计算机断层扫描(PET/CT)在评估巨细胞动脉炎(GCA)复发患者疾病活动度方面的诊断效用。
纳入一名2018年诊断为GCA的90岁男性患者。记录人口统计学数据、疾病史以及实验室参数,包括可溶性VAP - 1(sVAP - 1)水平。患者接受了[镓]镓 - DOTA - Siglec - 9 PET/CT扫描。额外的影像学评估包括颞浅动脉及其分支、面部、腋窝、锁骨下、颈动脉和椎动脉的血管超声,以及主动脉的磁共振成像(MRI)。患者的sVAP - 1水平为284 ng/ml,而对照组为123 ng/ml(标准差±55)。[镓]镓 - DOTA - Siglec - 9 PET/CT扫描显示锁骨下动脉(SUVmax为2.5)、主动脉弓(2.9)和心脏(2.9)有示踪剂摄取增加。值得注意的是,降主动脉(3.5)的摄取增加在穿过膈肌时突然降至2.2,CT检查未观察到血管管径变化。注射[镓]镓 - DOTA - Siglec - 9耐受性良好。主动脉MRI未显示炎症累及迹象。
本研究首次将[镓]镓 - DOTA - Siglec - 9 PET/CT应用于GCA复发患者,显示锁骨下动脉和主动脉弓示踪剂摄取增强,且有局部突然降低,这在传统影像学中未出现。这些发现表明,[镓]镓 - DOTA - Siglec - 9 PET/CT在精确检测GCA复发期间受影响的血管组织炎症方面具有巨大潜力。